middl
east
respiratori
syndrom
coronaviru
merscov
emerg
pathogen
continu
caus
outbreak
arabian
peninsula
travel
region
rais
concern
global
pandem
could
occur
show
dna
vaccin
encod
first
amino
acid
merscov
spike
protein
induc
antigenspecif
humor
cellular
immun
respons
mice
three
immun
high
titer
neutral
antibodi
gener
without
adjuv
dna
vaccin
merscov
gene
markedli
increas
frequenc
antigenspecif
cell
secret
cytokin
dna
vaccin
immun
passiv
transfer
immun
serum
vaccin
mice
protect
mice
middl
east
respiratori
syndrom
mer
coronaviru
merscov
emerg
zoonot
viru
caus
agent
mer
merscov
first
identifi
saudi
arabia
mer
case
report
countri
sinc
februari
laboratoryconfirm
case
includ
death
relat
merscov
report
mortal
sever
famili
cluster
nosocomi
cluster
case
report
reveal
humantohuman
transmiss
merscov
rais
concern
merscov
global
pandem
current
licens
therapeut
vaccin
avail
highlight
need
effici
vaccin
merscov
date
sever
vaccin
candid
develop
viral
vectorbas
recombin
subunit
vaccin
dna
vaccin
dna
primeproteinboost
vaccin
revers
geneticsconstruct
recombin
coronaviru
vaccin
among
dna
vaccin
present
rang
uniqu
advantag
proper
antigen
protein
fold
rapid
design
product
costeffect
stabil
nonrefriger
temperatur
conveni
storag
ship
furthermor
report
dna
vaccin
induc
humor
cellular
immun
respons
merscov
sarscov
infect
merscov
first
lineag
betacoronaviru
known
infect
human
genom
merscov
encod
four
structur
proteinsspik
envelop
e
membran
nucleocapsid
n
protein
class
fusion
protein
form
protrud
spike
viru
surfac
compos
ntermin
subunit
ctermin
subunit
report
merscov
bind
host
cell
receptor
dipeptidyl
peptidas
independ
fold
receptor
bind
domain
rbd
local
within
subunit
moreov
protein
identifi
immunogen
antigen
merscov
play
import
role
induct
neutral
antibodi
antivir
tcell
respons
thu
protein
major
target
current
vaccin
develop
protect
mer
howev
previou
studi
demonstr
vaccin
base
fulllength
potenti
induc
harm
side
effect
caus
nonneutr
epitop
contrast
rbd
proteinbas
subunit
vaccin
abl
induc
neutral
antibodi
antivir
tcell
respons
merscov
infect
addit
superior
safeti
nevertheless
improv
immunogen
subunit
vaccin
found
necessari
use
appropri
adjuv
even
adjuv
combin
immun
enhanc
eg
human
igg
fc
optim
deliveri
rout
dose
ideal
mer
vaccin
induc
potent
neutral
antibodi
respons
without
induc
harm
immun
effect
virusenhanc
antibodi
immunopatholog
base
establish
background
previou
research
result
select
protein
target
dna
vaccin
develop
present
studi
design
construct
dna
vaccin
encod
subunit
merscov
evalu
antigenspecif
humor
cellular
immun
respons
induc
dna
vaccin
mice
investig
protect
efficaci
dna
vaccin
mous
model
follow
merscov
challeng
vaccin
mice
mice
receiv
immun
serum
infect
found
significantli
decreas
viru
load
lung
sixto
eightweekold
specif
pathogenfre
femal
balbc
mice
purchas
changchun
institut
biolog
product
co
gene
sequenc
encod
amino
acid
spike
protein
strain
merscov
genbank
access
synthes
sangon
biotech
compani
shanghai
china
synthet
fulllength
without
entir
cytoplasm
domain
fragment
respect
subclon
mammalian
express
vector
invitrogen
san
diego
ca
usa
gener
recombin
plasmid
fig
recombin
plasmid
amplifi
escherichia
coli
takara
dalian
china
purifi
use
endofre
plasmid
maxi
kit
qiagen
gmbh
shanghai
china
recombin
plasmid
dissolv
pb
final
concentr
vitro
transfect
vivo
anim
immun
plate
seed
cell
grown
confluenc
cell
respect
transfect
recombin
plasmid
empti
vector
use
lipofectamin
transfect
reagent
invitrogen
san
diego
ca
usa
accord
manufactur
instruct
cell
harvest
h
posttransfect
cell
lysat
prepar
use
ripa
lysi
buffer
solarbio
life
scienc
beij
china
accord
manufactur
instruct
separ
polyacrylamid
gel
transfer
onto
nitrocellulos
blot
membran
ge
healthcar
life
scienc
freiburg
germani
western
blot
analysi
use
mous
monoclon
antibodi
sino
biolog
beij
china
mous
monoclon
antibodi
ray
antibodi
biotech
beij
china
mice
randomli
divid
two
group
mice
experiment
group
inject
intramuscularli
im
quadricep
muscl
recombin
plasmid
pb
week
fig
mice
control
group
receiv
either
volum
pb
empti
vector
time
point
week
follow
primari
immun
mice
group
randomli
select
collect
serum
blood
sampl
collect
retroorbit
plexu
punctur
antimerss
antibodi
level
serum
measur
indirect
elisa
use
purifi
rbd
protein
coat
antigen
previous
describ
absorb
read
nm
valu
higher
control
group
consid
posit
one
week
follow
third
immun
serum
sampl
harvest
serial
dilut
dmem
gibco
san
diego
ca
usa
mix
pfu
merscov
h
incub
mixtur
ad
vero
cell
addit
h
permit
absorpt
cell
overlaid
agaros
contain
fb
dmem
incub
day
agaros
plug
remov
collect
viru
remain
plaqu
visual
crystal
violet
stain
two
week
follow
second
immun
mice
group
randomli
select
euthan
spleen
harvest
tissu
cultur
dish
teas
apart
singlecel
suspens
press
ml
syring
cell
cultur
rpmi
medium
gibco
san
diego
ca
usa
contain
fb
gibco
san
diego
ca
usa
stimul
without
recombin
merscov
rbd
protein
prokaryot
express
purifi
ninta
affin
chromatographi
thermo
usa
pass
endotoxin
remov
spin
column
endotoxin
level
measur
less
euml
use
gelclot
limulu
amebocyt
lysat
assay
follow
incub
co
h
splenocyt
produc
measur
use
mous
enzymelink
immunospot
elispot
kit
mabtech
ab
stockholm
sweden
accord
manufactur
instruct
spotform
cell
sfc
enumer
autom
elispot
reader
aid
elispot
readerispot
aid
gmbh
ger
two
week
follow
second
immun
splenocyt
mice
group
isol
cultur
cellsml
stimul
co
h
describ
presenc
protein
transport
inhibitor
contain
monensin
bd
bioscienc
franklin
va
usa
cell
label
equal
volum
dilut
clone
clone
two
week
follow
second
immun
splenocyt
mice
group
isol
cultur
cellsml
stimul
describ
incub
co
h
cellfre
cultur
supernat
harvest
level
measur
use
mous
enzymelink
immunosorb
assay
elisa
develop
kit
mabtech
ab
stockholm
sweden
accord
manufactur
instruct
mice
sensit
merscov
infect
prior
transduct
adenoviru
express
human
previous
describ
one
week
follow
third
immun
dna
vaccin
immun
mice
mice
given
immun
serum
harvest
week
follow
third
immun
transduc
day
intranas
challeng
pfu
merscov
lung
mice
group
remov
pb
day
postinfect
manual
homogen
viru
titer
clarifi
supernat
assay
vero
cell
express
pfug
tissu
balbc
mice
handl
complianc
guidelin
welfar
recombin
plasmid
express
differ
fragment
fulllength
merscov
obtain
verifi
restrict
enzym
digest
sequenc
express
merscov
spike
protein
cell
respect
transfect
recombin
plasmid
confirm
western
blot
fig
express
level
protein
significantli
higher
consid
differ
express
level
influenc
immun
respons
variou
construct
antibodi
respons
merscov
evalu
indirect
elisa
shown
endpoint
dilut
titer
three
dna
vaccin
construct
dna
vaccin
elicit
highest
antibodi
titer
immun
mice
fig
thu
select
experi
sera
immun
mice
strongli
react
merscov
rbd
protein
receiv
second
third
immun
reach
endpoint
titer
fig
shown
figur
signific
differ
observ
sampl
harvest
week
week
post
third
immun
indic
antibodi
respons
reach
plateau
determin
antibodi
immun
serum
could
neutral
merscov
infect
vitro
plaqu
reduct
neutral
assay
perform
use
serial
dilut
serum
sampl
serum
sampl
effici
neutral
merscov
infect
vitro
even
dilut
fig
result
demonstr
dna
vaccin
encod
merscov
gene
induc
potent
neutral
antibodi
respons
confirm
success
induc
antibodi
respons
mice
antigenspecif
cellular
immun
respons
evalu
elispot
assay
intracellular
cytokin
stain
ic
assay
splenocyt
harvest
two
week
post
second
immun
chose
time
rbdspecif
antibodi
respons
first
detect
week
second
immun
fig
specul
cell
respons
also
gener
time
expect
significantli
sfc
detect
splenocyt
treat
mice
fig
b
control
frequenc
cell
mice
inject
significantli
higher
mer
rbd
stimul
fig
similar
result
observ
cell
fig
f
result
demonstr
dna
vaccin
markedli
increas
frequenc
antigenspecif
cell
investig
antigenspecif
cellular
immun
respons
induc
dna
vaccin
cytokin
secret
splenocyt
assay
elisa
level
splenocyt
immun
group
significantli
higher
control
fig
b
c
data
demonstr
dna
vaccin
enhanc
secret
type
cytokin
type
cytokin
splenocyt
mous
model
use
evalu
protect
immun
dna
vaccin
efficaci
immun
serum
contain
neutral
antibodi
merscov
determin
viru
load
infect
lung
dna
vaccin
immun
serum
vaccin
mice
acceler
viru
clearanc
day
viru
titer
decreas
log
day
viru
clear
group
fig
b
aim
develop
new
vaccin
abl
elicit
potent
immun
respons
merscov
infect
consid
current
studi
compar
immunogen
differ
gene
fragment
mer
dna
vaccin
choos
three
mutant
merscov
protein
antigen
fulllength
extracellular
domain
three
dna
vaccin
construct
dna
vaccin
select
studi
sinc
elicit
highest
antibodi
titer
immun
mice
contain
major
neutral
epitop
made
effect
safe
target
mer
vaccin
develop
similar
dnabas
vaccin
adenoviru
vectorbas
vaccin
express
merscov
extracellular
domain
induc
stronger
neutral
antibodi
respons
compar
vector
express
fulllength
may
fragment
induc
humor
immun
respons
effici
full
length
sinc
solubl
easili
taken
b
cell
lymph
node
follicl
note
immun
induc
slightli
higher
antibodi
respons
mice
possibl
mutant
still
contain
transmembran
region
anchor
protein
membran
previou
studi
shown
partial
complet
remov
sarscov
cytoplasm
domain
remov
transmembran
domain
along
cytoplasm
domain
dna
vaccin
candid
increas
neutral
antibodi
respons
mice
indic
remov
cytoplasm
domain
may
result
nativ
function
relev
structur
vivo
consid
besid
influenc
express
level
differ
modif
merscov
protein
may
also
respons
increas
gener
neutral
antibodi
respons
data
show
dna
vaccin
induc
antigenspecif
immun
respons
igg
product
neutral
antibodi
gener
cytokin
secret
mice
high
level
neutral
antibodi
gener
follow
three
immun
without
adjuv
furthermor
dna
vaccin
administr
immun
serum
vaccin
mice
acceler
viru
clearanc
lung
suggest
neutral
antibodi
merscov
protein
protect
immun
serum
transfer
mediat
antibodydepend
enhanc
infect
mous
model
fig
chose
day
post
third
immun
challeng
mice
limit
access
lab
specul
sinc
antibodi
respons
reach
plateau
cell
respons
probabl
peak
time
point
well
would
diminish
quickli
third
immun
howev
could
potenti
limit
longterm
protect
experi
still
requir
evalu
efficaci
vaccin
sinc
emerg
mer
adapt
evolut
merscov
strain
report
current
studi
merscov
gene
sequenc
strain
select
high
homolog
publish
strain
worth
note
challeng
experi
dna
vaccin
immun
protect
mice
infect
merscov
emc
strain
indic
dna
vaccin
inde
induc
protect
immun
differ
merscov
strain
overal
construct
examin
dna
vaccin
encod
merscov
protein
studi
data
clearli
demonstr
dna
vaccin
induc
potent
protect
immun
respons
mice
vaccin
anim
show
visibl
sign
advers
effect
protect
efficaci
evalu
dna
vaccin
nonhuman
primat
well
camel
must
consid
futur
studi
result
strongli
support
use
protein
merscov
genebas
vaccin
develop
effect
target
abl
elicit
antigenspecif
humor
cellular
immun
respons
splenocyt
isol
two
week
follow
second
immun
stimul
purifi
rbd
protein
h
level
b
c
secret
splenocyt
measur
use
commerci
elisa
kit
n
micegroup
time
point
data
shown
mean
sd
analyz
unpair
student
test
p
p
p
